Kevin Honeycutt is the CEO and President of the Alliance for Cancer Gene Therapy where his principal role is to enhance the vision of ACGT and to spearhead ACGT’s current focus on funding the next generation of challenges brought by metastatic cancers and solid tumors. Prior to his role at ACGT, Mr. Honeycutt was the President and CEO of the Avon Breast Cancer Crusade and served as Executive Director of the Avon Foundation for Women. As founder and consultant of Honeycutt Partners, his clients included the American Diabetes Association, the Entertainment Industry Foundation, and the San Francisco AIDS Foundation. Mr. Honeycutt serves on the Board of Directors of Friends of Mozart. He is a past Board member of the UCLA Jonsson Cancer Center Foundation.